Sr. Director Preclinical Pharmacology

About Judo Bio

Judo Bio is a Series A funded biotechnology company pioneering the delivery of oligonucleotide medicines to the kidney to treat systemic and renal diseases. Our proprietary STRIKE platform (Selectively Targeting RNA Into Kidney) leverages the kidney-specific megalin receptor to enable precise, cell-targeted delivery of siRNA therapeutics. This innovative approach allows us to address historically intractable diseases by initially targeting solute transporters in proximal tubule epithelial cells, offering new hope for conditions such as metabolic disorders, diabetes, and cardiovascular disease.

Enabled by a network of high-caliber experts and internal talent, we are thoughtfully building a team of passionate, innovative, and energetic scientific champions to discover and develop therapeutics that have the potential to change the lives of patients and families.

Judo Bio is developing the next generation of RNA therapeutics by expanding targeted delivery beyond the liver. We are seeking a seasoned Toxicology leader to shape our nonclinical safety strategy for our ligand-siRNA conjugate programs and advance our growing pipeline.

This role will be a key member of the Senior Research Leadership Team and will collaborate closely across Discovery, Platform, and Development to deliver high-quality safety data that supports INDs and clinical progression. Title will be commensurate with experience.

• Lead the toxicology strategy across programs to support discovery, development candidate selection, IND-enabling activities.
• Design, oversee, and interpret GLP and non-GLP toxicology studies in partnership with external CROs.
• Provide scientific and strategic input on molecule design, dose selection, safety biomarkers, and risk assessment.
• Collaborate cross-functionally with Discovery, Biology, Chemistry, Platform, and Clinical teams to integrate toxicology insights into program decisions.
• Drive authorship and review of toxicology components for regulatory filings (INDs, CTAs, IBs).
• Build, mentor, and develop a high-performing toxicology and PK team aligned with Judo Bio’s scientific rigor and collaborative culture.
• Stay current with regulatory expectations and evolving safety considerations for oligonucleotide therapeutics

• Ph.D., D.V.M., or equivalent in Toxicology, Pharmacology, Pathology, or related field; DABT strongly preferred.
• 8+ years of biotech/pharma experience with leadership in toxicology or nonclinical development.
• Proven expertise in IND-enabling toxicology; experience with oligonucleotide or RNA-based therapeutics or kidney preferred.
• Strong understanding of GLP study design, safety pharmacology, DMPK, and translational safety.
• Exceptional communication skills and demonstrated ability to lead cross-functional collaboration.